Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 8,260 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Age Clear all
Completed No phase listed Observational

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

NCT00466063
View directory record Official record
Conditions
Anemia
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 5 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 29, 2026, 10:31 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

NCT04537884
View directory record Official record
Conditions
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Interventions
UBX1325
Drug
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Beverly Hills, California • Huntington Beach, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 29, 2026, 10:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric COVID Outcomes Study (PECOS)

NCT04830852
View directory record Official record
Conditions
Covid19, MIS-C Associated With COVID-19, MIS-C Multisystem Inflammatory Syndrome in Children, SARS-CoV2 Infection
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
0 Years to 21 Years
Enrollment
1,097 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 29, 2026, 10:31 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

End Diagnostic Overshadowing

NCT06608758
View directory record Official record
Conditions
Disabilities Multiple
Interventions
Electonic health record prompts with education, Standard of care
Behavioral · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
3 Years to 89 Years
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 29, 2026, 10:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Coagulation in Multiple Sclerosis

NCT01711255
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 29, 2026, 10:31 AM EDT
Not listed No phase listed Observational

Biomarkers of Acute Stroke in Clinic

NCT03897478
View directory record Official record
Conditions
Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Interventions
ISCDX blood test
Diagnostic Test
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 29, 2026, 10:31 AM EDT
Terminated No phase listed Observational

Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

NCT01077440
View directory record Official record
Conditions
Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Testicular Germ Cell Tumor
Interventions
DNA analysis, polymerase chain reaction, flow cytometry, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 29, 2026, 10:31 AM EDT
Completed No phase listed Observational

Near Infrared Spectroscopy (St02)

NCT01062685
View directory record Official record
Conditions
Septic Shock
Interventions
Near-infrared spectroscopy assessment
Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 29, 2026, 10:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

COVID-19 Antibody and Reinfection Study

NCT05365750
View directory record Official record
Conditions
COVID-19 Testing
Interventions
Not listed
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
4,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 29, 2026, 10:31 AM EDT
Completed No phase listed Observational Results available

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

NCT05858450
View directory record Official record
Conditions
Influenza, Human, COVID-19
Interventions
Comirnaty, Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,442,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 29, 2026, 10:31 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

NCT06102174
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Placebo, Active
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 60 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 29, 2026, 10:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

YMCA Exercise Intervention for Smoking Cessation Study

NCT03080090
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Aerobic exercise, Smoking Cessation Intervention
Behavioral
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 29, 2026, 10:31 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Dupilumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 10:31 AM EDT
Completed Phase 3 Interventional Results available

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

NCT01744782
View directory record Official record
Conditions
Cystinosis
Interventions
RP103
Drug
Lead sponsor
Amgen
Industry
Eligibility
Up to 6 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 29, 2026, 10:31 AM EDT
Completed Phase 1 Interventional

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

NCT00500344
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Lucentis (ranibizumab)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 29, 2026, 10:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Metagenomic Biomarkers in Rheumatoid Arthritis

NCT02544334
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Dental Plaque, Multi-dimensional health assessment questionnaire (MDHAQ), Saliva Collection
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 29, 2026, 10:31 AM EDT
Completed Not applicable Interventional Results available

Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations

NCT01218399
View directory record Official record
Conditions
Asthma
Interventions
Symbicort
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 29, 2026, 10:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Emotion Study/Substudy: Flexible Brain Study

NCT03872414
View directory record Official record
Conditions
Aging, Emotions, Parkinson Disease
Interventions
Anterior cingulate cortex activation, Primary auditory cortex activation
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 29, 2026, 10:31 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

NCT00499616
View directory record Official record
Conditions
Neuroblastoma
Interventions
carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, Isotretinoin, Surgery, Filgrastim
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 12 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 29, 2026, 10:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

NCT00294047
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
Cervarix, Placebo control
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
26 Years and older · Female only
Enrollment
5,752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
36
States / cities
Fountain Valley, California • Aurora, Colorado • Golden, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 29, 2026, 10:31 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of Ellacor® Micro-coring® Following Best Practices on Technique and Post-Procedural Care

NCT07260578
View directory record Official record
Conditions
Best Practices, Ellacor, Micro-coring Post Care, Ellacor Post Care
Interventions
ellacor Micro-Coring Technology
Device
Lead sponsor
Cytrellis Biosystems, Inc.
Industry
Eligibility
45 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 29, 2026, 10:31 AM EDT
Recruiting Phase 2Phase 3 Interventional

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943
View directory record Official record
Conditions
Lymphatic Malformations
Interventions
Alpelisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
18
States / cities
Oakland, California • Orange, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 29, 2026, 10:31 AM EDT
Completed Phase 3 Interventional Results available

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT01897233
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 29, 2026, 10:31 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients

NCT05514847
View directory record Official record
Conditions
Preeclampsia, Pregnancy Related
Interventions
Aspirin 81Mg Ec Tab, Aspirin 162Mg Ec Tab
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 29, 2026, 10:31 AM EDT